Biological markers of invasive breast cancer

Akiko Matsumoto, Hiromitsu Jinno, Tomofumi Ando, Taku Fujii, Tetsuya Nakamura, Junichi Saito, Maiko Takahashi, Tetsu Hayashida, Yuukou Kitagawa

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Biological markers for breast cancer are biomolecules that result from cancer-related processes and are associated with particular clinical outcomes; they thus help predict responses to therapy. In recent years, gene expression profiling has made themolecular classification of breast cancer possible. Classification of breast cancer by immunohistochemical expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 and Ki-67 is standard practice for clinical decision- making. Assessments of hormone receptor expression and human epidermal growth factor receptor 2 overexpression help estimate benefits from targeted therapies and have greatly improved prognoses for women with these breast cancer types. Although Ki-67 positivity is associated with an adverse outcome, its clear identification is an aid to optimal disease management. Standardization of testingmethodology to minimize inter-laboratory measurement variations is a remaining issue.Multigene assays provide prognostic information and identify those most likely to benefit from systemic chemotherapy. Incorporating molecular profiles with conventional pathological classification would bemore precise, and could enhance the clinical development of personalized therapy in breast cancer.

Original languageEnglish
Article numberhyv153
Pages (from-to)99-105
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume46
Issue number2
DOIs
Publication statusPublished - 2016 Feb 1

Fingerprint

Biomarkers
Breast Neoplasms
Gene Expression Profiling
Progesterone Receptors
Disease Management
Estrogen Receptors
Therapeutics
Hormones
Drug Therapy
Neoplasms
human ERBB2 protein

Keywords

  • Biomarkers
  • Estrogen receptor
  • HER2
  • Ki-67
  • Progesterone receptor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Matsumoto, A., Jinno, H., Ando, T., Fujii, T., Nakamura, T., Saito, J., ... Kitagawa, Y. (2016). Biological markers of invasive breast cancer. Japanese Journal of Clinical Oncology, 46(2), 99-105. [hyv153]. https://doi.org/10.1093/jjco/hyv153

Biological markers of invasive breast cancer. / Matsumoto, Akiko; Jinno, Hiromitsu; Ando, Tomofumi; Fujii, Taku; Nakamura, Tetsuya; Saito, Junichi; Takahashi, Maiko; Hayashida, Tetsu; Kitagawa, Yuukou.

In: Japanese Journal of Clinical Oncology, Vol. 46, No. 2, hyv153, 01.02.2016, p. 99-105.

Research output: Contribution to journalArticle

Matsumoto, A, Jinno, H, Ando, T, Fujii, T, Nakamura, T, Saito, J, Takahashi, M, Hayashida, T & Kitagawa, Y 2016, 'Biological markers of invasive breast cancer', Japanese Journal of Clinical Oncology, vol. 46, no. 2, hyv153, pp. 99-105. https://doi.org/10.1093/jjco/hyv153
Matsumoto A, Jinno H, Ando T, Fujii T, Nakamura T, Saito J et al. Biological markers of invasive breast cancer. Japanese Journal of Clinical Oncology. 2016 Feb 1;46(2):99-105. hyv153. https://doi.org/10.1093/jjco/hyv153
Matsumoto, Akiko ; Jinno, Hiromitsu ; Ando, Tomofumi ; Fujii, Taku ; Nakamura, Tetsuya ; Saito, Junichi ; Takahashi, Maiko ; Hayashida, Tetsu ; Kitagawa, Yuukou. / Biological markers of invasive breast cancer. In: Japanese Journal of Clinical Oncology. 2016 ; Vol. 46, No. 2. pp. 99-105.
@article{ca81b158726d4696857467ab62e12a25,
title = "Biological markers of invasive breast cancer",
abstract = "Biological markers for breast cancer are biomolecules that result from cancer-related processes and are associated with particular clinical outcomes; they thus help predict responses to therapy. In recent years, gene expression profiling has made themolecular classification of breast cancer possible. Classification of breast cancer by immunohistochemical expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 and Ki-67 is standard practice for clinical decision- making. Assessments of hormone receptor expression and human epidermal growth factor receptor 2 overexpression help estimate benefits from targeted therapies and have greatly improved prognoses for women with these breast cancer types. Although Ki-67 positivity is associated with an adverse outcome, its clear identification is an aid to optimal disease management. Standardization of testingmethodology to minimize inter-laboratory measurement variations is a remaining issue.Multigene assays provide prognostic information and identify those most likely to benefit from systemic chemotherapy. Incorporating molecular profiles with conventional pathological classification would bemore precise, and could enhance the clinical development of personalized therapy in breast cancer.",
keywords = "Biomarkers, Estrogen receptor, HER2, Ki-67, Progesterone receptor",
author = "Akiko Matsumoto and Hiromitsu Jinno and Tomofumi Ando and Taku Fujii and Tetsuya Nakamura and Junichi Saito and Maiko Takahashi and Tetsu Hayashida and Yuukou Kitagawa",
year = "2016",
month = "2",
day = "1",
doi = "10.1093/jjco/hyv153",
language = "English",
volume = "46",
pages = "99--105",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Biological markers of invasive breast cancer

AU - Matsumoto, Akiko

AU - Jinno, Hiromitsu

AU - Ando, Tomofumi

AU - Fujii, Taku

AU - Nakamura, Tetsuya

AU - Saito, Junichi

AU - Takahashi, Maiko

AU - Hayashida, Tetsu

AU - Kitagawa, Yuukou

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Biological markers for breast cancer are biomolecules that result from cancer-related processes and are associated with particular clinical outcomes; they thus help predict responses to therapy. In recent years, gene expression profiling has made themolecular classification of breast cancer possible. Classification of breast cancer by immunohistochemical expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 and Ki-67 is standard practice for clinical decision- making. Assessments of hormone receptor expression and human epidermal growth factor receptor 2 overexpression help estimate benefits from targeted therapies and have greatly improved prognoses for women with these breast cancer types. Although Ki-67 positivity is associated with an adverse outcome, its clear identification is an aid to optimal disease management. Standardization of testingmethodology to minimize inter-laboratory measurement variations is a remaining issue.Multigene assays provide prognostic information and identify those most likely to benefit from systemic chemotherapy. Incorporating molecular profiles with conventional pathological classification would bemore precise, and could enhance the clinical development of personalized therapy in breast cancer.

AB - Biological markers for breast cancer are biomolecules that result from cancer-related processes and are associated with particular clinical outcomes; they thus help predict responses to therapy. In recent years, gene expression profiling has made themolecular classification of breast cancer possible. Classification of breast cancer by immunohistochemical expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 and Ki-67 is standard practice for clinical decision- making. Assessments of hormone receptor expression and human epidermal growth factor receptor 2 overexpression help estimate benefits from targeted therapies and have greatly improved prognoses for women with these breast cancer types. Although Ki-67 positivity is associated with an adverse outcome, its clear identification is an aid to optimal disease management. Standardization of testingmethodology to minimize inter-laboratory measurement variations is a remaining issue.Multigene assays provide prognostic information and identify those most likely to benefit from systemic chemotherapy. Incorporating molecular profiles with conventional pathological classification would bemore precise, and could enhance the clinical development of personalized therapy in breast cancer.

KW - Biomarkers

KW - Estrogen receptor

KW - HER2

KW - Ki-67

KW - Progesterone receptor

UR - http://www.scopus.com/inward/record.url?scp=84961613761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961613761&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyv153

DO - 10.1093/jjco/hyv153

M3 - Article

C2 - 26486826

AN - SCOPUS:84961613761

VL - 46

SP - 99

EP - 105

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 2

M1 - hyv153

ER -